Boufassa F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, et al. Blunted response to combination antiretroviral therapy in HIV elite controllers: An international HIV controller collaboration. PLoS One. 17 janv 2014;9(1). Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24465584
Boulle A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, et al. Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. PLoS Med. 1 sept 2014;11(9). Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25203931
Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, et al. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology. 8 juill 2014;83(2):134‑41. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24907236
Denis B, Guiguet M, De Castro N, Mechaï F, Revest M, Mahamat A, et al. Critical importance of long-term adherence to care in HIV infected patients in the cART era: New Insights from Pneumocystis jirovecii pneumonia cases over 2004-2011 in the FHDH-ANRS CO4 cohort. Vol. 9, PLoS ONE. Public Library of Science; 2014. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24727746
Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, et al. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis. 1 mai 2014;58(9):1312‑21. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24457342
Hleyhel M, Hleyhel M, Bouvier AM, Belot A, Tattevin P, Pacanowski J, et al. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS. 10 sept 2014;28(14):2109‑18. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25265077
IeDEA and ART Cohort Collaborations, Avila D, Althoff KN, Mugglin C, Wools-Kaloustian K, Koller M, et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr. 1 janv 2014;65(1):e8-16. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24419071
Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, et al. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis. 15 juill 2014;59(2):287‑97. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24771333
Lang S, Mary-Krause M, Partisani M, Gilquin J, Simon A, Cotte L, et al. Is impaired kidney function an independent predictor of the risk of myocardial infarction in HIV-infected individuals? AIDS. 24 août 2014;28(13):1987‑9. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25259706
Lodi S, Del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, et al. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries. AIDS. 23 oct 2014;28(16):2461‑73. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25265230
Mary-Krause M, Grabar S, Liévre L, Abgrall S, Billaud E, Boué F, et al. Cohort profile: French hospital database on HIV (FHDH-ANRS CO4). Int J Epidemiol. 20 août 2014;43(5):1425‑36. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24550249
May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, et al. Cohort profile: Antiretroviral therapy cohort collaboration (ART-CC). Int J Epidemiol. 2014;43(3):691‑702. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/23599235
Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 15 mai 2014;28(8):1181‑91. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24901259
Natural History Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals. AIDS. 1 juin 2014;28(9):1351‑6. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24959963
Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, et al. Evaluation of rapid progressors in HIV infection as an extreme phenotype. J Acquir Immune Defic Syndr. 1 sept 2014;67(1):15‑21. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24872130
Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, et al. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. PLoS One. 28 janv 2014;9(1). Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/24489776
Pantazis N, Porter K, Costagliola D, De Luca A, Ghosn J, Guiguet M, et al. Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. lancet HIV. déc 2014;1(3):e119-26. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/26424120
Potard V, Rey D, Poizot-Martin I, Mokhtari S, Pradier C, Rozenbaum W, et al. Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis. J Int AIDS Soc. 25 sept 2014;17(1):19070. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/25261780
van der Helm JJ, Geskus R, Lodi S, Meyer L, Schuitemaker H, Gunsenheimer-Bartmeyer B, et al. Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. lancet HIV. oct 2014;1(1):e41-8. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/26423816
